Prin

ted

on re

cycl

ed p

aper

PE

FC -

Pho

tos

créd

its: F

otol

ia -

Eur

asan

té -

Gra

phi

c D

esig

n: L

aure

nce

Labo

rie h

ttp:

//llo

gra�

st.u

ltra-

book

.com

/

AGENDA

For the third time, BioFIT brings to international actors in the life sciences

a meeting place between public and private actors and keeps achie-

ving to foster the emergence of new and innovative projects and products.

This 2014 edition is the event not to be missed for animal health, diabetes,

personalized medicine and biomaterials actors... The desire to join forces

has brought actors from these various sectors to partner with

BioFIT organizers and bring the most relevant public and private audience

to Lille next December 2nd and 3rd. On the menu, partnering activity with

pre-screened one-to-one meetings, a conference program tackling

subjects dealing with collaborative research, new funding sources and

new approaches to technology transfer, a presenting session offering the

possibility to present key technologies, licensing opportunities and product

development.

BioFIT 2014 will gather over 800 attendees from 35 countries, including

leading companies and professionals from pharma, biotech, medtech,

IVD but also technology transfer, licensing and IP professionals, academia

and investors. Thanks to the quality and diversity of its participants,

BioFIT looks certain to generate excellent collaborating opportunities that

will ful� ll the wishes of its attendance.

We invite you all to join us at BioFIT 2014 for a fruitful and enjoyable

two-day event full of learning, meetings and partnership opportunities!

Etienne VERVAECKE,General Commissioner of BioFIT 2014

and Eurasanté General Manager

December 2 & 3 2014 • Lille • FRANCE

A 360°approach to build life sciences

partnerships

Organized by In cooperation with

www.biofi t-event.com

llBoth the industry and academia want to speed up innovation and build collabora-tions on the long-term in order to push innovation to market. However some drawbacks are encountered in this pro-cess. What is to be done to drive inno-vation in Europe? Can the scouting be improved? How important is the valua-tion process and are the criteria used identical among all actors?

TRACK 1EMERGE, LAST AND DELIVER:

BEST PRACTICES IN COLLABORATIVE RESEARCH

TRACK 2EARLY STAGE INNOVATION: NEW ROUTES TO FUNDING

SOURCES

TRACK 3CREATIVE SOLUTIONS

FOR TRANSFERRING INNOVATION TO MARKET: TTO’S AND

INDUSTRY’S NEW APPROACHES

8:00 am Registration and Exhibition opening Welcome coffee

9:00 amBiotech meets

Medtech: a future perspective

Driving innovation in Europe: using Horizon

2020 program

11:00 am

Emerge & happen: creative solutions

to dif� cult problems in deal making

The valuation process: do all stakeholders use

the same criteria?

12:30 pm Lunch

2:00 pm

Make it work and last: how to best apply strategic alliance

management

New practices from the VC industry in

sourcing innovation

3:30 pm Coffee Break

4:00 pmScouting innovation: academia push and

industry pull

The road less travelled: new approaches to � nance early stage

innovation

5:30 pm Closure of BioFIT 2014

In a dif� cult economic climate, � nancing innovation seems to be ever more dif� cult especially during the maturation phase. What can be done to reverse this situation? Which are the new models that we see in the � eld? Are there new actors getting involved? Let’s � nd out how this environment is slowly changing and what will the future paint for early stage innovation � nancing?

Early stage innovation: new routes to funding sources

Creative solutions for transferring innovation to market:

TTO’s and industry’s new approaches

They will share their experiences They will share their experiences Adrian CARTER, Corporate Vice President of Global Research Networking, BOEHRINGER INGELHEIM (DE)

Garold BREIT, Owner, BREIT IDEAS (USA)

Jeffrey ULMER, Global Head, External Research, NOVARTIS VACCINES (USA)

Stefaan ALLEMEERSCH, Director Business Development, CENTRE FOR DRUG DESIGN AND DISCOVERY (CD3 – LEUVEN) (BE)

Duncan HOLMES, European Head, Discovery Partnerships with Academia, GSK (UK)

Christian TIDONA, Founder & Managing Director, BIOMED X INNOVATION CENTER (DE)

Kai SIMONS, Research Group Leader and Director Emeritus, MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS (DE)

Wen Hwa LEE, Strategic Alliances Manager, STRUCTURAL GENOMICS CONSORTIUM, UNIVERSITY OF OXFORD (UK)

Jesper TEGNER, Strategic Professor of Computational Medicine Center for Molecular Medicine, Department of Medicine, KAROLINSKA INSTITUTE (SE)

Titta ROSVALL-PUPLETT, Executive Director, EBE - EUROPEAN BIOPHARMACEUTICAL ENTERPRISES (BE)

Manfred KAUER, Senior Deputy Director, BIOREGIO STERN (DE)

Nicolas CARBONI, President, SATT CONECTUS ALSACE (FR)

Bernd STOWASSER, Head of Public Private Partnerships – External Innovation & Science Policy, SANOFI (DE)

Jacky VONDERSCHER, President, ENYO PHARMA (FR)

Pascale REDIG, Senior Sourcing Manager of Global Pharma R&D / Member of ASTP-Proton Professional Development Committee, JANSSEN PHARMACEUTICA / ASTP PROTON (BE)

Bruno FRANCOIS, Clinical Lead COMBACTE Consortium, CHU LIMOGES/INSERM (FR)

Stephan LENSKY, Corporate Vice President Strategic Transactions and Alliance Management, BOEHRINGER INGELHEIM (DE)

Mark WILSON, Partner, NORTON ROSE FULBRIGHT (USA)

Jürgen WALKENHORST, Head of Life Sciences, PROVENDIS GMBH (DE)

is introduced by Rémi DROLLER, Managing Partner, KURMA PARTNERS (FR)

is introduced by Jürgen WALKENHORST, Head of Life Sciences, PROVENDIS GMBH (DE)

Emerge, last and deliver: best practices in collaborative research

TRACK 1

Industry wants to improve its access to innovation, and is increasingly forming links with institutions that can help bridge the gap from research to market. But once put in place how do these collaborations work on the long-term? Do they deliver interesting results? Are they bene� cial for both parties? Let’s � nd out throughout a number of panels the in depths of these collaborations and the lessons learned when putting them in place.

is introduced by Tomas LANDH, Director, Strategy & Innovation Sourcing, Diabetes, NOVO NORDISK (DK)

TRACK 2

TRACK 3

Rémi DROLLER, Managing Partner, KURMA PARTNERS (FR)

Tony HICKSON, Managing Director, Technology Transfer, IMPERIAL INNOVATIONS (UK)

Matthieu COUTET, Managing Partner, INSERM TRANSFERT INITIATIVE (FR)

Francesco DE RUBERTIS, Partner and co-founder of the � rm’s life sciences practice, INDEX VENTURES (UK)

Christophe VAN VAECK, Principal, GIMV (BE)

Axel KALINOWSKI, Manager Continental Europe, LONDON STOCK EXCHANGE (UK)

Philippe CUPERS, Deputy Head of the «Strategy» Unit within the Health Directorate of the European Commission’s Directorate General for Research and Innovation, EUROPEAN COMMISSION (BE)

Aletta DEBERNARDI, Senior Advisor Research Funding, LEIDEN UNIVERSITY, LURIS (NL)

Hugh LAVERTY, Senior Scienti� c Project Manager, IMI - INNOVATIVE MEDICINES INITIATIVE (BE)

Georg KÄÄB, Cluster Manager Bavarian Biotech Cluster, BioM Corporate Communications, BIOM BIOTECH CLUSTER DEVELOPMENT GMBH (DE)

Carol L. MOORE, Director, IP and Licensing, MRC TECHNOLOGY (UK)

Ivan C. BAINES, Chief Operating Of� cer, MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS (DE)

Mark FARMERY, VP Business Development, KARO BIO (SE)

Ed SALTZMAN, President & Founder, DEFINED HEALTH (USA)

TRACK 1EMERGE, LAST AND DELIVER:

BEST PRACTICES IN COLLABORATIVE RESEARCH

TRACK 2EARLY STAGE INNOVATION:

NEW ROUTES TO FUNDING SOURCES

8:00 am Registration and Exhibition opening Welcome coffee

9:00 amBig consortia: how do they

work and what are their outcomes?

11:00 am

12:30 pm Lunch

2:00 pm New models for bridging the gap from research to market

Who will be funding the maturation phase

in the future?

3:30 pm Coffee Break

4:00 pm 5:30 pm

Looking ahead: can big data hold the key to breakthrough

treatments?

7:00 pm BioParty

D E C E M B E R 2 n d D E C E M B E R 3 r d

These two sessions

are linked

ONE-TO-ONE MEETINGS

ONE-TO-ONE MEETINGS

Plenary SessionAccessing innovation: how to build long-term partnerships?

PRESENTINGTECHNOLOGIES

ONE-TO-ONE MEETINGS

ONE-TO-ONE MEETINGS

These two sessions

are linked

l

The � rst international partnering event dedicated to technology transfer and collaborative research in Life Sciences gathering the right mix of attendees to boost up licensing deals and research collaborations. The 3rd edition of BioFIT will build on the success of previous editions with over 800 international participants from over 35 countries and is powered by

edition of BioFIT will build on the success of previous editions with , provided by EBD Group.

BioFIT 2014 is honored to receive the support of a prestigious Steering Committee composed of renowned international experts.

28% investors, clusters, services: Karolinska Development, Imperial Innovations,

Inserm Transfert Initiative, Index Ventures, Kurma Partners, De� ned Health, ASTP Proton,

EBE, EFPIA, Medicen Cluster, LEEM 38%

34%

28% 38% academic, TTO : Ascenion, Institut Curie, Institut Pasteur, Karolinska Institute, Max Planck Institute, MRC Technology, SATT, Provendis, Ghent University, Leiden University, Oxford University, Radboud University Medical Center

34% pharma, biotech, medtech: Boehringer Ingelheim, Eli Lilly, GSK,

GSK Vaccines, Ipsen Innovation, Karo Bio, LFB, Novartis Vaccines, Novo Nordisk,

Roche, Sano� , P� zer

Zeina ANTOUN, Clinical Research Director, GSK - GLAXOSMITHKLINE (FR)

Maria BOBADILLA, Senior Director, Extending Innovation Network, ROCHE (CH)

Sami CHTOUROU, Director of technology platforms and innovation, LFB (FR)

Maria M. FLOCCO, Senior Director, Head Strategic Research Partnerships Europe, PFIZER (FR)

Guy HELIN, Chief Business Of� cer, DELPHI GENETICS (BE)

Tomas LANDH, Director, Strategy & Innovation Sourcing, Diabetes Research Unit, NOVO NORDISK (DK)

Stephan LENSKY, Vice President Strategic Transaction & Alliances, BOEHRINGER INGELHEIM (DE)

Frédéric SCAEROU, Director, Scienti� c Affairs Oncology, IPSEN INNOVATION (FR)

Patrick TRICOLI, Senior Director Partnering and Innovation, SANOFI (FR)

Hervé ANSANAY, Business Developer, SATT NORD (FR)

Ivan BAINES, Chief Operating Of� cer, MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS (DE)

Garold BREIT, Owner, BREIT IDEAS (USA)

Nicolas CARBONI, President, SATT CONECTUS ALSACE (FR)

Jean-Luc CHAGNAUD, Healthcare Business Development Manager & IP Manager, AQUITAINE SCIENCE TRANSFERT (FR)

Esther LANGE, Project Manager, ASCENION (DE)

Richard BERGSTROM, Director General, EFPIA - EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS (BE)

Claude-Alain CUDENNEC, General Director, AFSSI - ASSOCIATION FRANÇAISE DES SOCIÉTÉS DE SERVICES ET D’INNOVATION (FR)

Isabelle DIAZ, Research & Biotechnology Director, LEEM / General Secretary, ARIIS - ALLIANCE POUR LA RECHERCHE ET L’INNOVATION DES INDUSTRIES DE SANTÉ (FR)

Marco FIORINI, General Secretary, AVIESAN - FRENCH NATIONAL ALLIANCE FOR LIFE SCIENCES AND HEALTH (FR)

Jean-Roch MEUNIER, General Director, MEDICEN COMPETITIVENESS CLUSTER (FR)

Benjamin NORDIN, Investor Relations Of� cer and Head of Business Analysis, KAROLINSKA DEVELOPMENT (SE)

Titta ROSVALL-PUPLETT, Executive Director, EBE - EUROPEAN BIOPHARMACEUTICAL ENTERPRISES (BE)

Anne ROY, Journalist, AEF – SPECIALIZED NEWS AGENCY (FR)

Emilie ROYERE, Director, EUROBIOMED (FR)

• • • S T E E R I N G C O M M I T T E E • • •

Industries Academia, TTOs Associations, Clusters, InvestorsAcademia, TTOs Clusters, Investors

• • • W H O W I L L Y O U M E E T ? • • •

Partnering Activity Hosted Events

PresentingTechnologies

Social Events

Exhibition

Workshops

Conferences

BioFITPass1 ful l pass to access al l act ivit ies, hosted events and workshops and signif icantly increase your contacts and optimize your encounters.

BioFIT registrat ion includes access to:

• Business Convention Onl ine par tner ing too l and ons i te one-to-one meet ings

• Conferences Un l imi ted access to a l l conferences, p lenar y sess ion, workshops

• Presenting technologies

• Exhibit ion area

• Lunch and coffee breaks

• BioParty

• Conference bag and Catalogue

REGISTRATION FEES (excl. VAT)

Mature companies € 999

Emerging companies (less than 3 years) € 399

TTO’s / Clusters / Research institutes

€ 849

Early Bird (Before September 30th, 2014)

€ 799

€ 319

€ 679

Register now at

www.biof i t-event .com

Confe rences and mee t ings o rgan i zed by the French Associat ion of Outsourc ing and Innova-t ive Companies to enhance susta inable co l la-b o r a t i o n b e t w e e n E u r o p e a n i n d u s t r i a l l i f e sc iences and R&D stakeholders.

Conferences and meet ings to s t imulate acade-mia industr y in teract ion and ident i fy in i t ia t ives t ha t can acce l e ra t e t he pace o f i nnova t i onin the d iabetes area.

European Genomic Institute for Diabetes

European Genomic Institute for Diabetes

EGID, 3rd international symposium, Meta-inflamation in diabetes and its complications

T h e t h e m e s d e v e l o p e d w i l l b e o n m e t a -inf lammation in d iabetes and i ts compl icat ions, organ ized by the European Genomic Ins t i tu te for D iabetes (E .G. I .D. ) .

December 2 & 3 2014 Lille • FRANCE

Conferences A 360°approach to build life sciences partnerships

Conference on “wound heal ing”

A conference organized by the European trans-nat iona l pro ject B iomat- IN to suppor t innova-t ion in b iomater ia ls

Final conference of Perso-Med project

The f ina l conference of a European t ransnat io-nal pro ject to foster cross-border R&D partner-sh ips in personal i zed medic ine

Meet ings organized by the French Assoc iat ion for Animal Heal th Industr y to in i t ia te h igh- level exchanges be tween research depar tments o f the veter inar y medic ine, d iagnost ics industr y, publ ic research and b io technology companies.

R&D dating for animal health and innovation

French Innovation Services Event

Innovation in Diabetes: European Action Summit

State of the Art Conferences for scientists

R&D dating for animal health and innovation

French Innovation Services Event

Innovation in Diabetes: European Action Summit

State of the Art Conferences for scientists

December 2nd December 3rd

Host

ed E

vent

sW

orks

hops

ValorisationCo

nsortium de

Thématique

Biotechnologie-Industrie-Organisation Deutschland e.V.

CMYK

Blue: 100/15/0/35Orange: 0/75/90/0

FEBiotecF e d e r a c i ó n E s p a ñ o l a d e B i o t e c n ó l o g o s

GOLD

BRONZE

CONTRIBUTING

SPONSORS

SUPPORTERS

INSTITUTIONALPARTNERS

December 2 & 3 2014 • Lille • FRANCE

Prin

ted

on re

cycl

ed p

aper

PE

FC -

Pho

tos

créd

its: F

otol

ia -

Eur

asan

té -

Gra

phi

c D

esig

n: L

aure

nce

Labo

rie h

ttp:

//llo

gra�

st.u

ltra-

book

.com

/

THEY SUPPORT US

Event Management & Conferences:

Marion SIGIER +33 (0)3 59 39 01 84 msigier@bio� t-event.com

Registration& Sponsorship:

Thom TRAN +33 (0)3 59 39 01 87 ttran@bio� t-event.com

Registration & Partnership:

Margaux SATOLA +33 (0)3 59 39 01 82 msatola@bio� t-event.com

Event Venue

Lille Grand Palais1 bd des Cités UniesF-59777 Lille-EuralilleFRANCE

www.biofi t-event.com

Partnering Activity Hosted Events

PresentingTechnologies

Social Events

Exhibition

Workshops

Conferences

BioFITPass1 ful l pass to access al l act ivit ies, hosted events and workshops and signif icantly increase your contacts and optimize your encounters.

BioFIT registrat ion includes access to:

• Business Convention Onl ine par tner ing too l and ons i te one-to-one meet ings

• Conferences Un l imi ted access to a l l conferences, p lenar y sess ion, workshops

• Presenting technologies

• Exhibit ion area

• Lunch and coffee breaks

• BioParty

• Conference bag and Catalogue

REGISTRATION FEES (excl. VAT)

Mature companies € 999

Emerging companies (less than 3 years) € 399

TTO’s / Clusters / Research institutes

€ 849

Early Bird (Before September 30th, 2014)

€ 799

€ 319

€ 679

Register now at

www.biof i t-event .com

Confe rences and mee t ings o rgan i zed by the French Associat ion of Outsourc ing and Innova-t ive Companies to enhance susta inable co l la-b o r a t i o n b e t w e e n E u r o p e a n i n d u s t r i a l l i f e sc iences and R&D stakeholders.

Conferences and meet ings to s t imulate acade-mia industr y in teract ion and ident i fy in i t ia t ives t ha t can acce l e ra t e t he pace o f i nnova t i onin the d iabetes area.

European Genomic Institute for Diabetes

European Genomic Institute for Diabetes

EGID, 3rd international symposium, Meta-inflamation in diabetes and its complications

T h e t h e m e s d e v e l o p e d w i l l b e o n m e t a -inf lammation in d iabetes and i ts compl icat ions, organ ized by the European Genomic Ins t i tu te for D iabetes (E .G. I .D. ) .

December 2 & 3 2014 Lille • FRANCE

Conferences A 360°approach to build life sciences partnerships

Conference on “wound heal ing”

A conference organized by the European trans-nat iona l pro ject B iomat- IN to suppor t innova-t ion in b iomater ia ls

Final conference of Perso-Med project

The f ina l conference of a European t ransnat io-nal pro ject to foster cross-border R&D partner-sh ips in personal i zed medic ine

Meet ings organized by the French Assoc iat ion for Animal Heal th Industr y to in i t ia te h igh- level exchanges be tween research depar tments o f the veter inar y medic ine, d iagnost ics industr y, publ ic research and b io technology companies.

R&D dating for animal health and innovation

French Innovation Services Event

Innovation in Diabetes: European Action Summit

State of the Art Conferences for scientists

R&D dating for animal health and innovation

French Innovation Services Event

Innovation in Diabetes: European Action Summit

State of the Art Conferences for scientists

December 2nd December 3rd

Host

ed E

vent

sW

orks

hops